Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

In vitro pancreatic differentiation of pluripotent mammalian cells

A pluripotent cell and cell technology, applied in animal cells, vertebrate cells, artificial cell constructs, etc.

Active Publication Date: 2015-07-01
CAMBRIDGE ENTERPRISE LTD
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite this extensive knowledge, the molecular mechanisms that orchestrate the extracellular signaling pathways of transcriptional networks in pancreatic or hepatic progenitor cells, especially in humans, remain to be elucidated, and hPSCs may be uniquely positioned to accomplish this. a main task

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In vitro pancreatic differentiation of pluripotent mammalian cells
  • In vitro pancreatic differentiation of pluripotent mammalian cells
  • In vitro pancreatic differentiation of pluripotent mammalian cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0201] experiment

[0202] hESC and hIPSC culture conditions.

[0203] hESCs (H9 purchased from WiCell) and hIPSCs (BBHX8, A1ATD-1, JRO1D) (Rashid S et al. (2010) J. Clin. Invest. 120: 3127-3136) were grown in defined media (Brons et al. ( 2007) Nature 448:191-195). Cells were passaged weekly with collagenase IV and maintained in chemically defined medium (CDM) supplemented with activin A (10 ng / ml) and FGF2 (12 ng / ml) as previously described (Brons et al. )middle. differentiated as figure 1 in the manner described. Medium was changed daily throughout the differentiation process. After the DE stage (Stage 1), the cells were treated with SB-431542 (10 μM; Tocris), FGF10 (50 ng / ml; AutogenBioclear), all-trans retinoic acid (RA, 2 μM; Sigma) and Tau Protein (50ng / ml; R&D Systems) was cultured in advanced DMEM (Invitrogen) for 3 days. In stage 3, the cells were incubated with high-grade DMEM+human FGF10 (50ng / ml; AutogenBioclear), all-trans retinoic acid (RA, 2μM; Sigma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.

Description

technical field [0001] The present invention relates to inducing pancreatic differentiation in pluripotent mammalian cells in vitro. Background technique [0002] The generation of pancreatic β cells represents a major goal of regenerative medicine. Indeed, a large supply of these cells would enable the development of cell-based diabetes therapies, currently limited by a lack of donor organs and the difficulty of expanding insulin-secreting cells in vitro. Human pluripotent stem cells (hPSCs) of embryonic origin (human embryonic stem cells or hESCs) [1] or generated from reprogrammed somatic cells (human induced pluripotent stem cells or hIPSCs) [2] offer the prospect of bypassing these limitations. In fact, these cells are capable of unlimited proliferation in vitro while maintaining the ability to differentiate into various cell types, including pancreatic progenitors [3-6]. However, robust methods that allow the generation of homogenous populations of these cells under ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/071
CPCC12N2506/02C12N2501/16C12N2501/115C12N5/0676C12N2501/155A61P1/18A61P3/10A61K35/39C12N5/0678C12N2500/30C12N2500/38C12N2501/117C12N2501/40C12N2501/41C12Q1/6881C12Q2600/158C12Q2600/16G01N33/5038G01N33/507G01N33/74
Inventor 鲁多维奇·瓦利耶卓欣樺
Owner CAMBRIDGE ENTERPRISE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com